Literature DB >> 34210168

Changes in Brain Functional and Effective Connectivity After Treatment for Breast Cancer and Implications for Intervention Targets.

Nicholas S Phillips1,2, Vikram Rao3, Lorie Kmetz3, Ruben Vela3,4, Sarah Medick3, Kevin Krull1,2, Shelli R Kesler3,4,5.   

Abstract

Background: Patients with breast cancer frequently report cognitive impairment both during and after completion of therapy. Evidence suggests that cancer-related cognitive impairments are related to widespread neural network dysfunction. The default mode network (DMN) is a large conserved network that plays a critical role in integrating the functions of various neural systems. Disruption of the network may play a key role in the development of cognitive impairment.
Methods: We compared neuroimaging and neurocognitive data from 43 newly diagnosed primary breast cancer patients (mean age = 48, standard deviation [SD] = 8.9 years) and 50 frequency-matched healthy female controls (mean age = 50, SD = 10 years) before treatment and 1 year after treatment completion. Functional and effective connectivity measures of the DMN were obtained using graph theory and Bayesian network analysis methods, respectively.
Results: Compared with healthy females, the breast cancer group displayed higher global efficiency and path length post-treatment (p < 0.03, corrected). Breast cancer survivors showed significantly lower performance on measures of verbal memory, attention, and verbal fluency (p < 0.05) at both time points. Within the DMN, local brain network organization, as measured by edge-betweenness centralities, was significantly altered in the breast cancer group compared with controls at both time points (p < 0.0001, corrected), with several connections showing a significant group-by-time effect (p < 0.003, corrected). Effective connectivity demonstrated significantly altered patterns of neuronal coupling in patients with breast cancer (p < 0.05). Significant correlations were seen between hormone blockade therapy, radiation therapy, chemotherapy cycles, memory, and verbal fluency test and edge-betweenness centralities. Discussion: This pattern of altered network organization in the default mode is believed to result in reduced network efficiency and disrupted communication. Subregions of the DMN, the orbital prefrontal cortex and posterior memory network, appear to be at the center of this disruption and this could inform future interventions. Impact statement This prospective study is the first to investigate how post-treatment changes in functional and effective connectivity in the regions of default mode network are related to cancer therapy and measures of memory and verbal learning in breast cancer patients. We demonstrate that the interactions between treatment, brain connectivity, and neurocognitive outcomes coalesce around a subgroup of brain structures in the orbital frontal and parietal lobe. This would suggest that interventions that target these regions may improve neurocognitive outcomes in breast cancer survivors.

Entities:  

Keywords:  breast cancer; cognitive impairment; connectome; drug-related side effects and adverse reactions; survivorship

Mesh:

Year:  2021        PMID: 34210168      PMCID: PMC9131353          DOI: 10.1089/brain.2021.0049

Source DB:  PubMed          Journal:  Brain Connect        ISSN: 2158-0014


  101 in total

1.  Predicting regional neurodegeneration from the healthy brain functional connectome.

Authors:  Juan Zhou; Efstathios D Gennatas; Joel H Kramer; Bruce L Miller; William W Seeley
Journal:  Neuron       Date:  2012-03-21       Impact factor: 17.173

2.  Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls.

Authors:  Shelli R Kesler; Jeffrey S Wefel; S M Hadi Hosseini; Maria Cheung; Christa L Watson; Fumiko Hoeft
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

3.  Chemotherapy altered brain functional connectivity in women with breast cancer: a pilot study.

Authors:  Julie A Dumas; Jenna Makarewicz; Geoffrey J Schaubhut; Robert Devins; Kimberly Albert; Kim Dittus; Paul A Newhouse
Journal:  Brain Imaging Behav       Date:  2013-12       Impact factor: 3.978

4.  Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer.

Authors:  Michiel B de Ruiter; Liesbeth Reneman; Willem Boogerd; Dick J Veltman; Frits S A M van Dam; Aart J Nederveen; Epie Boven; Sanne B Schagen
Journal:  Hum Brain Mapp       Date:  2010-07-28       Impact factor: 5.038

5.  A Call for a Neuroscience Approach to Cancer-Related Cognitive Impairment.

Authors:  Todd S Horowitz; Jerry Suls; Melissa Treviño
Journal:  Trends Neurosci       Date:  2018-06-12       Impact factor: 13.837

Review 6.  Oxytocin, brain physiology, and functional connectivity: a review of intranasal oxytocin fMRI studies.

Authors:  Richard A I Bethlehem; Jack van Honk; Bonnie Auyeung; Simon Baron-Cohen
Journal:  Psychoneuroendocrinology       Date:  2012-11-15       Impact factor: 4.905

7.  Functional connectome biotypes of chemotherapy-related cognitive impairment.

Authors:  Shelli R Kesler; Melissa L Petersen; Vikram Rao; Rebecca A Harrison; Oxana Palesh
Journal:  J Cancer Surviv       Date:  2020-03-10       Impact factor: 4.442

Review 8.  Network dysfunction in Alzheimer's disease and frontotemporal dementia: implications for psychiatry.

Authors:  Juan Zhou; William W Seeley
Journal:  Biol Psychiatry       Date:  2014-02-04       Impact factor: 13.382

9.  Disrupted brain network functional dynamics and hyper-correlation of structural and functional connectome topology in patients with breast cancer prior to treatment.

Authors:  Shelli R Kesler; Marjorie Adams; Melissa Packer; Vikram Rao; Ashley M Henneghan; Douglas W Blayney; Oxana Palesh
Journal:  Brain Behav       Date:  2017-02-06       Impact factor: 2.708

10.  Functional and structural connectome properties in the 5XFAD transgenic mouse model of Alzheimer's disease.

Authors:  Shelli R Kesler; Paul Acton; Vikram Rao; William J Ray
Journal:  Netw Neurosci       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.